Servier, Taiho sales and marketing update

The U.K.’s NICE issued final guidance recommending Lonsurf trifluridine/tipiracil from Servier to treat metastatic colorectal cancer (mCRC) in patients previously treated with or who are not candidates for some chemotherapies, anti-VEGF agents and anti- EGFR therapies. The recommendation is in line with a July final appraisal determination. Lonsurf is an oral combination of trifluridine (FTD), an antineoplastic nucleoside analog, and tipiracil, an inhibitor of the FTD-degrading enzyme thymidine phosphorylase (see BioCentury, Aug.1). ...